Nymox Pharmaceutical Corp. (NYMX) on Monday released positive new clinical trial data from responder analysis of its pooled multi-center U.S. Phase 2 studies of NX-1207, indicating durable early responder benefits from Nymox's innovative drug treatment for benign prostatic hyperplasia or BPH.
The study concerned patients who reported a 6 point or better improvement in BPH Symptom Score improvement within a month of treatment. At follow-up, that is 14 months on average post-treatment, proportionally there were over 4.3 times as many NX-1207 early responders who had maintained a 6 point or better improvement in symptom score and who did not require further BPH treatment of any kind as compared to placebo controls.
NX-1207 is a novel drug developed by Nymox which is in Phase 3 development for the treatment of BPH. The drug has successfully completed a series of blinded controlled multi-center U.S. clinical trials where it has been found to produce improvements that are about double that reported for currently approved BPH drugs. NX-1207 is administered by a urologist in an office procedure that takes only a few minutes and involves little or no pain or discomfort.
For comments and feedback: editorial@rttnews.com